Supplementary Table II. Recurrence, final dose, and patient-borne cost outcomes after stepwise baricitinib tapering
Description
Recurrence patterns, time to recurrence, final baricitinib dose, and patient-borne cost reductions according to tapering outcome. Data are presented as median (IQR) or n/N (%), unless otherwise indicated. Tapering failure was defined as recurrence requiring re-escalation to baricitinib 4 mg daily. On-drug success was defined as continued baricitinib use at a reduced dose without re-escalation to 4 mg daily at last follow-up; off-drug success was defined as discontinuation without re-escalation. Minor and major recurrence were defined as recurrent SALT scores of <5 and ≥5, respectively, and percentages were calculated among patients with recurrence within each column. Time to recurrence was summarized among patients with recurrence. Final dose distributions were calculated among tapering successes. Cost estimates are specific to Korean drug pricing and reimbursement conditions. Per-patient cost reduction was calculated as [1 − actual patient-borne baricitinib cost / estimated patient-borne cost assuming uninterrupted 4-mg daily treatment over the same period] × 100; per-patient absolute cost saving was calculated as the corresponding cost difference. Costs are reported in Korean won (KRW). For reference, US$1 = KRW 1,477.93 on April 30, 2026. Unit costs were KRW 20,172 for a 4-mg tablet, approximately US$13.65, and KRW 13,448 for a 2-mg tablet, approximately US$9.10. Tapering costs were calculated according to each patient’s actual prescribed dosing schedule. Values are descriptive. Abbreviations: IQR, interquartile range; KRW, Korean won; NA, not applicable.